Cargando…
1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
BACKGROUND: CAR T -cell therapy (CTT) is a novel treatment for B-cell cancers. CTT patients (pt) are at risk of infection due to neutropenia, cytokine release syndrome (CRS), and CAR T-cell related encephalopathy syndrome (CRES), which are treated with steroids and tocilizumab (anti-IL-6). This is a...
Autores principales: | Garner, Will, Samanta, Palash, Dorritie, Kathleen, Sehgal, Alison, Winfield, Denise, Agha, Mounzer, Boudreau, Robert, Nguyen, Minh Hong T, Haidar, Ghady |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776724/ http://dx.doi.org/10.1093/ofid/ofaa439.1291 |
Ejemplares similares
-
Invasive Fungal Infections after Anti-CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy: State of the Evidence and Future Directions
por: Garner, Will, et al.
Publicado: (2021) -
202. The Impact and Safety of Discontinuing Routine Surveillance Blood Culture Monitoring in Allogeneic Hematopoietic Cell Transplant Recipients
por: Garner, Will, et al.
Publicado: (2021) -
925. Infectious Complications Following Chimeric Antigen Receptor (CAR) T-cell Therapy
por: Trottier, Caitlin, et al.
Publicado: (2021) -
Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021) -
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)